# US 2014/0155465 A1 · Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155465 A1
- Document ID: US20140155465A1
- Status: Published application
- Kind: A1
- Application number: 13/802,035
- Filed: 2013-03-13
- Published: 2014-06-05
- Earliest claimed: 2012-11-30
- Assignees: Geron Corporation
- Applicants: Geron Corporation
- Inventors: Ekaterina BASSETT; Bart Burington; Hui Wang; Kevin Eng
- Web page: https://patentgrep.com/patent/US20140155465A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds.

## Claims

### Claim 1

A method of selecting an individual diagnosed with or suspected of having cancer who will benefit from treatment with a telomerase inhibitor, the method comprising:
a. determining relative telomere length by analyzing the relative length of telomeric nucleic acids in cancer cells present in a biological sample from the individual; and
b. selecting an individual who will benefit from treatment with a telomerase inhibitor when the average relative telomere length in the cancer cells present in a biological sample from the individual is determined to be in the 50th percentile or less of a relative telomere length range determined from one or more known standards.

### Claim 2

A method of treating an individual diagnosed with or suspected of having cancer, the method comprising:
a. determining relative telomere length by analyzing the relative length of telomeric nucleic acids in cancer cells present in a biological sample from the individual;
b. selecting an individual who will benefit from treatment with a telomerase inhibitor when the average relative telomere length in the cancer cells present in a biological sample from the individual is determined to be in the 50th percentile or less of a relative telomere length range determined from one or more known standards; and
c. administering a therapeutically effective amount of the telomerase inhibitor to the individual.

### Claim 3

A method of treating an individual diagnosed with or suspected of having cancer, the method comprising: administering a therapeutically effective amount of a telomerase inhibitor to the individual when the average relative telomere length in cancer cells present in a biological sample from the individual has been determined to be in the 50th percentile or less of a relative telomere length range determined from one or more known standards.

### Claim 4 (depends on 2)

The method of claim 2, wherein the telomerase inhibitor comprises an oligonucleotide.

### Claim 5 (depends on 4)

The method of claim 4, wherein the oligonucleotide is complementary to the RNA component of telomerase.

### Claim 6 (depends on 5)

The method of claim 5, wherein the oligonucleotide is 10-20 base pairs in length and comprises at least one N3′→P5′ thiophosphoramidate internucleoside linkage.

### Claim 7 (depends on 5)

The method of claim 5, wherein the telomerase inhibitor is Imetelstat.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is a solid tumor.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer is non-small cell lung cancer, small cell lung cancer, bladder cancer, upper gastrointestinal cancer, gastric cancer, gallbladder cancer, ovarian cancer, glioblastoma, a sarcoma or a hematological cancer.

### Claim 10 (depends on 2)

The method of claim 2, wherein the telomerase inhibitor is administered with a pharmaceutically acceptable excipient.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering to the individual a therapeutically effective amount of one or more additional cancer therapeutic agents.

### Claim 12 (depends on 1)

The method of claim 1, wherein average telomere length is determined by qPCR, telo-FISH, or Southern Blot.

### Claim 13 (depends on 1)

The method of claim 1, wherein the individual is a human.

### Claim 14 (depends on 1)

The method of claim 1, wherein said one or more known standards are characterized cell lines.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cell lines are selected from the group consisting of:
M14 cells, A549 cells, SK-5 cells, and Ovcar5 cells.

### Claim 16 (depends on 1, 14)

The method of claim 14, wherein the characterized cell lines are selected from cell lines representative of the type of biological sample of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the characterized cell lines are non-small cell lung cancer cell lines, hepatocellular cell lines, or ovarian cell lines.

### Claim 18 (depends on 1)

The method of claim 1, wherein said one of more of the known standards is a telomere length range established from a plurality of naturally occurring tumors from a plurality of individuals.

### Claim 19 (depends on 18)

The method of claim 18, wherein said cancer cells from a plurality of naturally occurring tumors is of the same type as the cancer cells present in the biological sample from the individual.

### Claim 20 (depends on 1)

The method of claim 1 wherein the telomere length in the cancer cells present in the biological sample is determined to be in the 40th percentile, 35th percentile, 30th percentile, 25th percentile, 20th percentile, 15th percentile, 10th percentile, 5th percentile, or less than the telomere length range.
